PYXS

Pyxis is a clinical-stage oncology company with no meaningful product revenue — the $13.9M FY2025 'revenue' is collaboration/milestone income (down 14.2% YoY and not commercial sales), so the 11.9x P/S is a meaningless artifact. The business is defined by its lead ADC, micvotabart pelidotin (MICVO), whose MD&A reports genuinely encouraging early signals in R/M head-and-neck cancer: a 50% confirmed ORR in six evaluable dose-escalation patients (one CR, two PRs, 100% DCR) and positive Dec-2025 expansion data. But this is Phase 1 evidence in single-digit-to-13-patient cohorts of heavily pre-treated patients — hypothesis-generating, not de-risked. R&D rose 25.4% to $73.7M as the program advances, which is the right spend but the wrong balance sheet to fund it.

The disqualifying issue is liquidity. Cash fell to $15.4M while operating cash flow ran -$63.5M for the year — on that burn the company has only a fraction of a year of runway from the FY2025 balance sheet, and total assets already collapsed 41.8% and equity 55.8% YoY. Accumulated deficit is -$443M. A raise is not a catalyst risk, it is a near-certainty, and with a $165M market cap and 62.8M shares the dilution to fund even one more year of operations would be severe and likely at a distressed price. Today's -7.7% move and a $2.63 price near the low end of clinical-biotech valuations reflect this overhang.